Sven-Erik Dahlén
Corporate Officer/Principal en Karolinska Institutet .
Relaciones activas
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Peter Sjöstrand | M | 78 |
Karolinska Institutet
| - |
Thomas Perlmann | M | - |
Karolinska Institutet
| - |
Klas Kärre | M | 70 |
Karolinska Institutet
| - |
Hans Lennart Rudolf Wigzell | M | 86 |
Karolinska Institutet
| 29 años |
Anna Martling | M | 55 |
Karolinska Institutet
| - |
Björn Allan Beermann | M | 83 |
Karolinska Institutet
| - |
Carani Sanjeevi | M | 66 |
Karolinska Institutet
| 28 años |
Magnus Westgren | M | 73 |
Karolinska Institutet
| 18 años |
Magnus Jaderberg | M | - |
Karolinska Institutet
| - |
Scott Boyer | M | 62 |
Karolinska Institutet
| - |
Tord Stefan Erik Arver | M | 72 |
Karolinska Institutet
| - |
Kerstin Uvnäs Moberg | M | 80 |
Karolinska Institutet
| - |
Jan Matthew Balmanno Carlstedt-Duke | M | 71 |
Karolinska Institutet
| - |
Jan Peter Andersson | M | 73 |
Karolinska Institutet
| 14 años |
Hans Ehrsson | M | - |
Karolinska Institutet
| - |
Per Magnus Gerde | M | - |
Karolinska Institutet
| - |
Ewa Björling | M | 63 |
Karolinska Institutet
| - |
Hans Hassle | M | - |
Karolinska Institutet
| - |
Lars Ährlund-Richter | M | 72 |
Karolinska Institutet
| - |
Håkan Mellstedt | M | 82 |
Karolinska Institutet
| 25 años |
Pär Nordlund | M | 66 |
Karolinska Institutet
| 19 años |
Eva Andersson-Dubin | M | - |
Karolinska Institutet
| - |
Hans Wiksell | M | - |
Karolinska Institutet
| - |
Gert Auer | M | - |
Karolinska Institutet
| - |
Johan Edvard Lundin | M | 60 |
Karolinska Institutet
| 12 años |
Bengt Ingemar Samuelsson | M | 90 |
Karolinska Institutet
| - |
Marie Wickman-Chanteraeu | M | 69 |
Karolinska Institutet
| - |
Elias Arnér | M | - |
Karolinska Institutet
| - |
Han Jing Xie | M | 54 |
Karolinska Institutet
| - |
Rune Toftgard | M | - |
Karolinska Institutet
| - |
Lena Von Koch | F | - |
Karolinska Institutet
| - |
Susana Borrás | F | - |
Karolinska Institutet
| - |
Anders Blanck | M | - |
Karolinska Institutet
| - |
Petter Brodin | M | - |
Karolinska Institutet
| - |
Caroline Ingre | M | 47 |
Karolinska Institutet
| - |
Martin Schalling | M | - |
Karolinska Institutet
| - |
Peter Hjelmström | M | 51 |
Karolinska Institutet
| - |
Magnus Sjoegren | M | - |
Karolinska Institutet
| - |
Knut Martin Henschen Ingvar | M | 69 |
Karolinska Institutet
| - |
Märta Segerdahl | M | 68 |
Karolinska Institutet
| - |
Anders Gabrielsen | M | 58 |
Karolinska Institutet
| - |
Anna-Karin Edstedt Bonamy | M | 50 |
Karolinska Institutet
| 10 años |
Peter Sackey | M | 53 |
Karolinska Institutet
| - |
Ronald Li | M | - |
Karolinska Institutet
| 8 años |
Olle Kämpe | M | 68 |
Karolinska Institutet
| - |
Jan-Ingmar Flock | M | 75 |
Karolinska Institutet
| - |
Ralf Morgenstern | M | 72 |
Karolinska Institutet
| - |
Joakim Tedroff | M | 63 |
Karolinska Institutet
| - |
John Arne Øvretveit | M | - |
Karolinska Institutet
| - |
Sven Fredrik Lindskog | M | 71 |
Karolinska Institutet
| - |
Carl Johan Bertil Sundberg | M | 66 |
Karolinska Institutet
| - |
Lars-Olof Hansson | M | 80 |
Karolinska Institutet
| 26 años |
Bo Angelin | M | 73 |
Karolinska Institutet
| - |
Göran Tornling | M | 77 |
Karolinska Institutet
| - |
Andris Kreicbergs | M | - |
Karolinska Institutet
| - |
Kenneth R. Chien | M | - |
Karolinska Institutet
| - |
Rolf Valter Rikard Kiessling | M | 76 |
Karolinska Institutet
| 30 años |
Jonas Christopher Frisén | M | 58 |
Karolinska Institutet
| - |
Gunnar Magnus Modee Persson | M | 64 |
Karolinska Institutet
| 30 años |
Erna Möller | F | - |
Karolinska Institutet
| - |
Carola Elisabet Lemne | M | 66 |
Karolinska Institutet
| 26 años |
Rolf Lewensohn | M | - |
Karolinska Institutet
| - |
Per Axel Tomas Södersten | M | 79 |
Karolinska Institutet
| - |
Jan Orwar | M | 60 |
Karolinska Institutet
| - |
Stig Gösta Ollmar | M | 78 |
Karolinska Institutet
| 27 años |
Madeleine Olsson-Eriksson | M | 79 |
Karolinska Institutet
| - |
Bo-Ragnar Tolf | M | 74 |
Karolinska Institutet
| - |
Anders Vahlne | M | 78 |
Karolinska Institutet
| 30 años |
Matti Sällberg | M | 63 |
Karolinska Institutet
| 24 años |
Bernd Seizinger | M | 67 |
Karolinska Institutet
| - |
Anders Olof Adolf Ekblom | M | 70 |
Karolinska Institutet
| - |
Josef M. Miller | M | - |
Karolinska Institutet
| - |
David Rikard Martinsson Holmdahl | M | 71 |
Karolinska Institutet
| 16 años |
Erik Gustav Magnus Axelson | M | - |
Karolinska Institutet
| - |
John Wahren | M | - |
Karolinska Institutet
| - |
Graham Lappin | M | - |
Karolinska Institutet
| - |
Lennart Hammarstrom | M | - |
Karolinska Institutet
| - |
Ulf de Faire | M | - |
Karolinska Institutet
| - |
Mona Ståhle | M | - |
Karolinska Institutet
| - |
Gunvor Ester Ekman-Ordeberg | M | 80 |
Karolinska Institutet
| 23 años |
Torkel Klingberg | M | - |
Karolinska Institutet
| - |
Lars Gunnar Lannfelt | M | 75 |
Karolinska Institutet
| 31 años |
Lars Olov Larsson | M | - |
Karolinska Institutet
| - |
Edvard Smith | M | 73 |
Karolinska Institutet
| - |
Per M. Almqvist | M | - |
Karolinska Institutet
| - |
Erik Johan Frostegård | M | 65 |
Karolinska Institutet
| - |
Gunilla Anders Ekström | M | 66 |
Karolinska Institutet
| - |
Torgny H. Svensson | M | - |
Karolinska Institutet
| - |
Klas Gosta Wiman | M | - |
Karolinska Institutet
| - |
Ola Winqvist | M | 58 |
Karolinska Institutet
| - |
Lajos Gunnar Németh | M | 72 |
Karolinska Institutet
| 21 años |
Sten Nilsson | M | 76 |
Karolinska Institutet
| - |
Jan Anders Holgersson | M | - |
Karolinska Institutet
| - |
Håkan Elmqvist | M | - |
Karolinska Institutet
| - |
Lars Olson | M | - |
Karolinska Institutet
| - |
Gráfico relacional
Relaciones con varias empresas
Antiguas relaciones
Nombre | Sexo | Edad | Empresas relacionadas | Colaboración |
---|---|---|---|---|
Hans Marcus Bosson | M | 56 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 12 años |
Jan Anders Vedin | M | 82 |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 años |
Kent Alan Gossett | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 años |
Bengt Sparf | M | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 10 años |
Helena Lindberg | F | - |
Resistentia Pharmaceuticals AB
Resistentia Pharmaceuticals AB Pharmaceuticals: MajorHealth Technology Resistentia Pharmaceutical's business strategy is to develop and commercialize immunotherapy as a second generation therapy to monoclonal antibodies for the treatment of chronic diseases. Resistentia’s most advanced program is an immunotherapy against allergy/asthma – a growing health problem with a large unmet medical need. In contrast to existing therapies, which are largely symptomatic, Resistentia’s novel immunotherapeutic approach targets the cause of the allergic reactions, rather than the symptoms. In addition, Resistentia is developing an immunotherapy for the treatment of rheumatoid arthritis. The project is currently in discovery phase. | 4 años |
Estadísticas
País | Relaciones | % del total |
---|---|---|
Suecia | 100 | 100.00% |
Antigüedad de la relación
Activas
Pasados
Hombre
Mujer
Administradores
Ejecutivos
Origen de las relaciones
- Bolsa de valores
- Insiders
- Sven-Erik Dahlén
- Red Personal